Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Moleculin Biotech, Inc. (MBRX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.1500-0.0300 (-2.54%)
At close: 04:00PM EDT
1.1000 -0.05 (-4.35%)
After hours: 06:46PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close1.1800
Open1.1400
Bid1.1300 x 800
Ask1.1900 x 1100
Day's Range1.0710 - 1.2199
52 Week Range1.0200 - 3.0800
Volume107,773
Avg. Volume97,534
Market Cap32.898M
Beta (5Y Monthly)1.78
PE Ratio (TTM)N/A
EPS (TTM)-0.6410
Earnings DateNov 09, 2022 - Nov 14, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for MBRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Moleculin Biotech, Inc.
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverIn this edition, Skyworks soars, Big Biopharma builds immunity to headwinds, and Baidu and the cloud; and Harmonic Drive Systems, Elekta, and Nabtesco.
    Rating
    Fair Value
    Economic Moat
    4 months agoMorningstar
View more
  • PR Newswire

    Moleculin Biotech to Present at the Virtual Investor Innovations in Acute Myeloid Leukemia (AML) Spotlight Event

    Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter V. Kemp, Founder, President, CEO and Chairman, and Wolfram C. M. Dempke, MD, PhD, MBA, European Chief Medical Officer of Moleculin will participate in the Virtual Investor Innovations in Acute Myeloid Leukemia Spotlight Event on Wednesday, September 28, 2022 at 11:00 AM ET.

  • PR Newswire

    Moleculin Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that members of management will virtually present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, NY September 8-10, 2022.

  • PR Newswire

    Moleculin to Present at the H.C. Wainwright 24th Annual Global Investment Conference

    Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the H.C. Wainwright 24th Annual Global Investment Conference being held in New York, NY and virtually on September 12-14, 2022.

Advertisement
Advertisement